Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRx continuing to make strong progress with another 'very, very good quarter'

Cameron Reynolds, president and chief executive of VolitionRx Limited (NYSE MKT:VNRX), discusses with Proactive the firm's second quarter update as well as recent company highlights.

Meet ImmuPharma PLC, Synairgen plc, Tissue Regenix Group PLC, Tissue Regenix Group PLC and WideCells Group at our event, London, 02 November 2017. Register here »
Why Invest In VolitionRx? Read More Here

Register here to be notified of future VolitionRx articles
View full VNRX profile View Profile

VolitionRx Timeline

September 14 2017
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use